HAG
JAZZ icon

HighPoint Advisor Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

HighPoint Advisor Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,579
Closed -$438K – 852
2025
Q4 		$438K Sell
2,579
-72
-3% -$11K 0.01% 706
2025
Q3 		$349K Buy
2,651
+12
+0.5% +$1.44K 0.02% 484
2025
Q2 		$280K Buy
2,639
+16
+0.6% +$1.74K 0.01% 538
2025
Q1 		$305K Buy
2,623
+67
+3% +$8.74K 0.02% 480
2024
Q4 		$332K Buy
2,556
+456
+22% +$53.7K 0.02% 473
2024
Q3 		$232K Buy
2,100
+46
+2% +$5.04K 0.01% 571
2024
Q2 		$231K Buy
2,054
+93
+5% +$10.2K 0.01% 550
2024
Q1 		$222K Sell
1,961
-30
-2% -$3.67K 0.02% 573
2023
Q4 		$240K Buy
+1,991
New +$248K 0.02% 529

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

HighPoint Advisor Group's JAZZ Position: Q1 2026 in Review

HighPoint Advisor Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 2,579 shares — an estimated $438K sold.

HighPoint Advisor Group first reported a position in JAZZ in Q4 2023 and held it in 9 quarters. The position peaked at $438K in Q4 2025. 574 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • HighPoint Advisor Group reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HighPoint Advisor Group sold 2,579 Jazz Pharmaceuticals shares in Q1 2026, an estimated $438K.
  • HighPoint Advisor Group first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • HighPoint Advisor Group's Jazz Pharmaceuticals position peaked at $438K in Q4 2025.
  • 574 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.